FINWIRES · TerminalLIVE
FINWIRES

Outlook Therapeutics Says Lytenava Gets FDA Approval for Retinal Disease Treatment

By

Outlook Therapeutics (OTLK) said Friday the US Food and Drug Administration has approved Lytenava for the treatment of neovascular age-related macular degeneration, commonly known as wet AMD, which is a chronic, progressive retinal disease.

The company said it expects the approval to grant Lytenava 12 years of reference product exclusivity under the Biologics Price Competition and Innovation Act.

Outlook Therapeutics said it is now executing the commercial launch of Lytenava and expects to make the ophthalmic formulation of bevacizumab available to eligible US patients before year-end.

Price: $1.58, Change: $+0.26, Percent Change: +19.32%

Related Articles

Wire

Business First Bancshares Q2 Earnings, Revenue Rise; Shares Drop After Hours

Business First Bancshares (BFST) reported core Q2 earnings late Thursday of $0.71 per diluted share, up from $0.66 a year earlier.Analysts polled by FactSet expected $0.70.Revenue in the three months ended June 30, expressed as net interest income plus total other income, rose to $91.8 million from $81.5 million.Four analysts expected $91.3 million.The company's shares fell 3.3% in after-hours trading.

$BFST
Wire

RingCentral Q2 Adjusted Earnings, Revenue Rise; FY Guidance Increases

RingCentral (RNG) reported Q2 non-GAAP net income late Thursday of $1.22 per diluted share, up from $1.06 a year earlier.Analysts polled by FactSet expected $1.16.Revenue in the three months ended June 30 rose to $657 million from $620 million a year earlier.Analysts expected $650.5 million.RingCentral expects Q3 non-GAAP EPS of $1.25 to $1.30 on revenue of $664 million to $670 million.Analysts expect EPS of $1.25 on revenue of $663.2 million.The company raised full-year non-GAAP EPS guidance to the range of $4.96 to $5.10 on revenue of $2.635 billion to $2.646 billion. The previous forecast was EPS of $4.85 to $5.01 on revenue of $2.62 billion to $2.64 billion.Analysts expect EPS of $4.92 on revenue of $2.63 billion.RingCentral shares rose 1.2% in after-hours trading.

$RNG
Wire

Robert Half Q2 Net Income, Revenue Fall; Shares Drop After Hours

Robert Half (RHI) reported Q2 net income late Thursday of $0.26 per share, down from $0.41 a year earlier.Analysts polled by FactSet expected $0.26.Revenue in the three months ended June 30 fell to $1.34 billion from $1.37 billion a year earlier.Analysts expected $1.32 billion.The company's shares fell 5.3% in after-hours trading.

$RHI